Another novel drug for diabetes Another GLP 1 Analogu | UPDATES IN MEDICINE
Another novel drug for diabetes Another GLP 1 Analogue
● Cardiovascular and Renal Outcomes with Efpeglenatide
This trial compared weekly injections of efpeglenatide, an exendin-based glucagon-like peptide-1 receptor agonist, at a dose of 4 or 6 mg with placebo in participants with known type 2 diabetes and either a history of cardiovascular disease or current kidney disease plus at least one other cardiovascular risk factor. The risk of cardiovascular events was lower with efpeglenatide. #endocrinology #diabetes
